Picture of Argenica Therapeutics logo

AGN — Argenica Therapeutics Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-10.95%
3m-28.62%
6m-7.66%
1yrn/a
Volume Change (%)
10d/3m-26.71%
Price vs... (%)
52w High-50.98%
50d MA-7.9%
200d MA-6.8%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value6.86
Price to Tang. Book6.86
Price to Free Cashflown/a
Price to Sales25,058.99
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-58.1%
Return on Equity-86.66%
Operating Margin-212271.23%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Argenica Therapeutics EPS forecast chart

Profile Summary

Argenica Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been demonstrated in pre-clinical animal models of stroke showing a reduction in brain cell death and is in the process of being verified for its safety and toxicity before commencing Phase I clinical trials in humans.

Directors

Last Annual
June 30th, 2021
Last Interim
December 31st, 2021
Incorporated
November 20th, 2019
Public Since
January 1st, 1970
No. of Shareholders
894
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
73,172,250
Blurred out image of a map
Address
4/117 Broadway, NEDLANDS, 6009
Web
https://argenica.com.au/
Phone
+61 893293396
Auditors
RSM Australia Partners

AGN Share Price Performance

Upcoming Events for AGN

Argenica Therapeutics Ltd Annual Shareholders Meeting

Similar to AGN

Picture of Actinogen Medical logo

Actinogen Medical

au flag iconAustralian Stock Exchange - SEATS

Picture of Adalta logo

Adalta

au flag iconAustralian Stock Exchange - SEATS

Picture of Alterity Therapeutics logo

Alterity Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Amplia Therapeutics logo

Amplia Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Anatara Lifesciences logo

Anatara Lifesciences

au flag iconAustralian Stock Exchange - SEATS

FAQ

Or unlock with your email

Or unlock with your email